Developer docs
API playgroundTry for free, no card

Search company profiles

Novan

Full company profile

uuid0005b49

Namestring
Novan
Legal namestring
Novan, Inc.
Websiteurl
novan.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Novan, Inc. was a clinical-stage dermatology drug development company founded in 2008 and headquartered in Morrisville (later Durham), North Carolina. The company's core technology was a proprietary nitric oxide-releasing platform (NITRICIL) developed to deliver topical therapeutics for skin diseases. Its lead asset was berdazimer gel, 10.3% (SB206), a first-in-class nitric oxide-releasing topical gel targeting molluscum contagiosum, a contagious skin infection primarily affecting children under 14 with US prevalence estimated at 5.1%-11.5%. Novan pursued FDA approval with a PDUFA goal date of January 5, 2024 and reported a target FDA review milestone of the same date.

In March 2022, Novan acquired EPI Health, a dermatology-focused commercial company, to build out commercial infrastructure and broaden its dermatology footprint beyond SB206. The company funded operations through a series of equity and warrant-linked financings, including a $40M raise in June 2021, a $15M registered direct offering in June 2022, and a $6M round in March 2023, alongside historical capital from Malin Corporation and Aspire Capital Partners. Cumulative disclosed funding exceeded $200M across multiple rounds dating back to 2009.

In July 2023, Novan filed for Chapter 11 bankruptcy protection and entered a stalking horse asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of its assets. Following the asset sale, the SB206 asset was ultimately approved by the FDA and commercialized in early 2024 as Zelsuvmi by Pelthos Therapeutics (a Ligand-affiliated entity), marketed as the first FDA-approved at-home prescription treatment for molluscum contagiosum. As of the input data, Novan as an independent operating entity has ceased, with the commercial franchise continuing under Pelthos across Zelsuvmi, Xepi, and Xeglyze.

Short descriptiontext

Novan was a clinical-stage dermatology company that developed a proprietary nitric oxide-releasing platform (NITRICIL) to treat skin diseases, with lead asset berdazimer gel (SB206) for molluscum contagiosum; it filed for Chapter 11 in 2023 and sold assets to Ligand Pharmaceuticals, which commercialized the product as Zelsuvmi via Pelthos Therapeutics.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
topical dermatology therapeutics, nitric oxide drug delivery, prescription skin treatments, molluscum contagiosum therapy, clinical-stage pharmaceuticals
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Topical Dermatology Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Novan was a clinical-stage pharmaceutical company developing topical therapeutics based on its proprietary nitric oxide-releasing (NITRICIL™) technology platform. Its lead asset, berdazimer gel 10.3% (SB206 / ZELSUVMI), is a topical prescription treatment for molluscum contagiosum, a contagious skin infection primarily affecting children. Following FDA approval in early 2024, the product was commercialized by Pelthos Therapeutics (Ligand Pharmaceuticals' platform) as the first at-home prescription treatment for molluscum contagiosum.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Target FDA review goal of January 5, 2024 for berdazimer gel (SB206) for molluscum contagiosum
Product overview1 text field

Novan was a dermatology company focused on developing innovative therapeutic products for unmet medical needs, particularly skin conditions. The company's primary asset was SB206 (berdazimer gel, 10.3%), an investigational treatment for molluscum contagiosum. Following Novan's Chapter 11 bankruptcy and asset sale to Ligand Pharmaceuticals, the product was commercialized by Pelthos Therapeutics as Zelsuvmi, which received FDA approval in early 2024.

Product and service2 records
1SB206 (berdazimer gel, 10.3%) / ZELSUVMI
CategoryTopical Dermatology Pharmaceuticals
Description

Topical gel prescription treatment for molluscum contagiosum, a contagious skin infection primarily affecting children under 14. Developed using Novan's proprietary NITRICIL™ nitric oxide-releasing platform.

2ZELSUVMI®
CategoryTopical Dermatology Pharmaceuticals
Description

FDA-approved at-home prescription topical treatment for molluscum contagiosum lesions in pediatric and adult patients. Marketed as a self-applied therapeutic reducing treatment burden.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-11
Description

Novan acquired EPI Health as part of its corporate expansion strategy in March 2022. This acquisition was intended to strengthen Novan's presence in the dermatology market.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the world's largest independent dermatology companies with a broad portfolio of prescription, aesthetics, and consumer skin care products. Operates broadly in the same dermatology therapeutics market as Novan's specialty focus.

TypeOthers
Description

Specialty pharma and royalty company that acquired substantially all of Novan's assets through the Chapter 11 stalking horse agreement. Direct relationship as acquirer of Novan's technology platform and SB206 asset.

TypeDirect peer
Description

Specialty dermatology pharma that developed Ycanth (cantharidin 0.7%), the other FDA-approved treatment for molluscum contagiosum. Most direct competitor to Novan's SB206/Zelsuvmi in the same indication and patient population.

TypeDirect peer
Description

Specialty dermatology pharmaceutical company developing and commercializing topical treatments for inflammatory skin conditions. Comparable as a small-cap, single-indication-focused dermatology pharma business model.

TypeDirect peer
Description

Clinical-stage dermatology company developing therapeutics for skin diseases including immuno-inflammatory conditions. Comparable small-cap specialty dermatology pharma business model.

TypeDirect peer
Description

Dermatology-focused pharmaceutical company developing topical therapies for skin diseases. Directly comparable specialty dermatology pharma profile with novel topical therapeutics.

TypeEmerging player
Description

Specialty dermatology therapeutics company that commercialized Zelsuvmi (formerly SB206) following Novan's asset sale to Ligand. Operates the same products and NITRICIL™ platform that Novan developed, and is the direct successor entity.

TypeBroad incumbent
Description

Global pharmaceutical company that acquired Anacor Pharmaceuticals, gaining a dermatology portfolio including topical antifungal and anti-inflammatory products. Relevant as a major pharma with established dermatology operations.

TypeBroad incumbent
Description

Large diversified pharmaceutical company with a significant dermatology franchise including topical treatments. Comparable as an established player with overlapping dermatology therapeutic capabilities.

TypeDirect peer
Description

Specialty dermatology company developing topical generics and innovative treatments for skin conditions including acne and actinic keratosis. Comparable specialty dermatology pharma focused on topical product development.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novan

Topical Dermatology Pharmaceuticalsnovan.com

Novan was a clinical-stage dermatology company that developed a proprietary nitric oxide-releasing platform (NITRICIL) to treat skin diseases, with lead asset berdazimer gel (SB206) for molluscum contagiosum; it filed for Chapter 11 in 2023 and sold assets to Ligand Pharmaceuticals, which commercialized the product as Zelsuvmi via Pelthos Therapeutics.

What Novan does

Novan, Inc. was a clinical-stage dermatology drug development company founded in 2008 and headquartered in Morrisville (later Durham), North Carolina. The company's core technology was a proprietary nitric oxide-releasing platform (NITRICIL) developed to deliver topical therapeutics for skin diseases. Its lead asset was berdazimer gel, 10.3% (SB206), a first-in-class nitric oxide-releasing topical gel targeting molluscum contagiosum, a contagious skin infection primarily affecting children under 14 with US prevalence estimated at 5.1%-11.5%. Novan pursued FDA approval with a PDUFA goal date of January 5, 2024 and reported a target FDA review milestone of the same date.

In March 2022, Novan acquired EPI Health, a dermatology-focused commercial company, to build out commercial infrastructure and broaden its dermatology footprint beyond SB206. The company funded operations through a series of equity and warrant-linked financings, including a $40M raise in June 2021, a $15M registered direct offering in June 2022, and a $6M round in March 2023, alongside historical capital from Malin Corporation and Aspire Capital Partners. Cumulative disclosed funding exceeded $200M across multiple rounds dating back to 2009.

In July 2023, Novan filed for Chapter 11 bankruptcy protection and entered a stalking horse asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of its assets. Following the asset sale, the SB206 asset was ultimately approved by the FDA and commercialized in early 2024 as Zelsuvmi by Pelthos Therapeutics (a Ligand-affiliated entity), marketed as the first FDA-approved at-home prescription treatment for molluscum contagiosum. As of the input data, Novan as an independent operating entity has ceased, with the commercial franchise continuing under Pelthos across Zelsuvmi, Xepi, and Xeglyze.

Novan firmographics

Firmographics
Name
Novan
Legal name
Novan, Inc.
Website
https://novan.com
Company type
Private
Founded year
2008
Operating status
Closed
Headcount range
51–100 employees
Short description
Novan was a clinical-stage dermatology company that developed a proprietary nitric oxide-releasing platform (NITRICIL) to treat skin diseases, with lead asset berdazimer gel (SB206) for molluscum contagiosum; it filed for Chapter 11 in 2023 and sold assets to Ligand Pharmaceuticals, which commercialized the product as Zelsuvmi via Pelthos Therapeutics.
Ownership category
akta.pro rank

Novan industry classification

Industry
Product category
Topical Dermatology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Topical dermatology therapeutics
  • Nitric oxide drug delivery
  • Prescription skin treatments
  • Molluscum contagiosum therapy
  • Clinical-stage pharmaceuticals

Where Novan is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Markets served

Novan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Novan product offering

Product offering

Core offering

Novan was a clinical-stage pharmaceutical company developing topical therapeutics based on its proprietary nitric oxide-releasing (NITRICIL™) technology platform. Its lead asset, berdazimer gel 10.3% (SB206 / ZELSUVMI), is a topical prescription treatment for molluscum contagiosum, a contagious skin infection primarily affecting children. Following FDA approval in early 2024, the product was commercialized by Pelthos Therapeutics (Ligand Pharmaceuticals' platform) as the first at-home prescription treatment for molluscum contagiosum.

Product overview

Novan was a dermatology company focused on developing innovative therapeutic products for unmet medical needs, particularly skin conditions. The company's primary asset was SB206 (berdazimer gel, 10.3%), an investigational treatment for molluscum contagiosum. Following Novan's Chapter 11 bankruptcy and asset sale to Ligand Pharmaceuticals, the product was commercialized by Pelthos Therapeutics as Zelsuvmi, which received FDA approval in early 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • SB206 (berdazimer gel, 10.3%) / ZELSUVMI Topical gel prescription treatment for molluscum contagiosum, a contagious skin infection primarily affecting children under 14. Developed using Novan's proprietary NITRICIL™ nitric oxide-releasing platform.
  • ZELSUVMI® FDA-approved at-home prescription topical treatment for molluscum contagiosum lesions in pediatric and adult patients. Marketed as a self-applied therapeutic reducing treatment burden.

Quantifiable outcome

  • Target FDA review goal of January 5, 2024 for berdazimer gel (SB206) for molluscum contagiosum

Companies that use Novan

Customer profile

Segments1 record

Ideal customer profiles1 record

Novan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Novan partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • EPI HealthcoreStrategic or Co-development Partner · 11 March 2022Novan acquired EPI Health as part of its corporate expansion strategy in March 2022. This acquisition was intended to strengthen Novan's presence in the dermatology market.

Scale indicators2 records

Recent moves8 records

Expansion highlights3 records

Novan competitors and assessment

Company assessment

Broad incumbents

  • Galderma: One of the world's largest independent dermatology companies with a broad portfolio of prescription, aesthetics, and consumer skin care products. Operates broadly in the same dermatology therapeutics market as Novan's specialty focus.
  • Pfizer (Anacor / dermatology portfolio): Global pharmaceutical company that acquired Anacor Pharmaceuticals, gaining a dermatology portfolio including topical antifungal and anti-inflammatory products. Relevant as a major pharma with established dermatology operations.
  • Bausch Health (Bausch + Lomb dermatology): Large diversified pharmaceutical company with a significant dermatology franchise including topical treatments. Comparable as an established player with overlapping dermatology therapeutic capabilities.

Others

  • Ligand Pharmaceuticals: Specialty pharma and royalty company that acquired substantially all of Novan's assets through the Chapter 11 stalking horse agreement. Direct relationship as acquirer of Novan's technology platform and SB206 asset.

Direct peers

  • Verrica Pharmaceuticals: Specialty dermatology pharma that developed Ycanth (cantharidin 0.7%), the other FDA-approved treatment for molluscum contagiosum. Most direct competitor to Novan's SB206/Zelsuvmi in the same indication and patient population.
  • Arcutis Biotherapeutics: Specialty dermatology pharmaceutical company developing and commercializing topical treatments for inflammatory skin conditions. Comparable as a small-cap, single-indication-focused dermatology pharma business model.
  • Aclaris Therapeutics: Clinical-stage dermatology company developing therapeutics for skin diseases including immuno-inflammatory conditions. Comparable small-cap specialty dermatology pharma business model.
  • Dermavant Sciences: Dermatology-focused pharmaceutical company developing topical therapies for skin diseases. Directly comparable specialty dermatology pharma profile with novel topical therapeutics.
  • Sol-Gel Technologies: Specialty dermatology company developing topical generics and innovative treatments for skin conditions including acne and actinic keratosis. Comparable specialty dermatology pharma focused on topical product development.

Emerging players

  • Pelthos Therapeutics: Specialty dermatology therapeutics company that commercialized Zelsuvmi (formerly SB206) following Novan's asset sale to Ligand. Operates the same products and NITRICIL™ platform that Novan developed, and is the direct successor entity.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Novan social profiles

Digital presence

Novan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novan leadership team

Management profile

Number of profiles

Profiles3 records

Novan subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Novan funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novan M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novan

What does Novan do?

Novan was a clinical-stage pharmaceutical company developing topical therapeutics based on its proprietary nitric oxide-releasing (NITRICIL™) technology platform. Its lead asset, berdazimer gel 10.3% (SB206 / ZELSUVMI), is a topical prescription treatment for molluscum contagiosum, a contagious skin infection primarily affecting children. Following FDA approval in early 2024, the product was commercialized by Pelthos Therapeutics (Ligand Pharmaceuticals' platform) as the first at-home prescription treatment for molluscum contagiosum.

Is Novan a public or private company?

Novan is a private company. It is classified as public and is currently closed.

When was Novan founded?

Novan was founded in 2008. It employs 51 to 100 people.

Where is Novan based?

Novan is headquartered in Morrisville, United States, in the North America region.

Who are Novan's main competitors?

Broad incumbents on record are Galderma, Pfizer (Anacor / dermatology portfolio) and Bausch Health (Bausch + Lomb dermatology). Ligand Pharmaceuticals is listed as an others. Direct peers are Verrica Pharmaceuticals, Arcutis Biotherapeutics, Aclaris Therapeutics, Dermavant Sciences and Sol-Gel Technologies. Pelthos Therapeutics is listed as an emerging player.

Does Novan have an API?

No public API is recorded for Novan.

What industry is Novan in?

Novan's product category is Topical Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGenital Warts Treatment Pipeline Shows Strong Momentum as 30+ Pharma Companies in the Race | DelveInsightDelveInsight published a pipeline report in 2025-2026 documenting over 30 pharmaceutical companies developing more than 30 pipeline therapies for the treatment of genital warts, a common sexually transmitted infection caused by human papillomavirus (HPV). In December 2025, Shanghai Bovax Biotechnology initiated a Phase 2 clinical trial for a 15-valent HPV recombinant vaccine in China, while Xiamen University announced a Phase III study in November 2025 for a recombinant HPV vaccine manufactured by Xiamen Innovax Biotech. Leading pipeline candidates include Verrica Pharmaceuticals' VP-102, Novan's SB206 (containing NVN1000), and Cassiopea's CB-06-02, representing diverse therapeutic approaches including drug-device combinations, topical antivirals, and immune modulators.GlobeNewswireDelisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics plc; UTA Acquisition Corporation; ANasdaq announced delisting of securities for Nymox Pharmaceutical, Aridis Pharmaceuticals, Novan, ViewRay, 9 Meters Biopharma, Nabriva Therapeutics, UTA Acquisition, AppHarvest, Yellow Corporation, Proterra, Amyris, Chain Bridge I, LatAmGrowth SPAC, and SpringBig Holdings. Each company's securities were suspended in July or August 2023 and had not traded since.BenzingaVerrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval - VerricaThe FDA approved Verrica Pharmaceuticals Inc's Ycanth (cantharidin) topical solution for molluscum contagiosum in adult and pediatric patients two years and older, marking the reintroduction of cantharidin as an FDA-approved dermatology product after it was previously available only through compounding pharmacies. Needham upgraded Verrica's stock to Buy from Hold with a $10 price target, projecting peak sales of $250 million based on 15% market share and $650 per applicator pricing. The analyst view Ycanth as unlikely to face near-term competition, noting that Novan Inc's potential competing product SB-206 has uncertain prospects following Novan's recent bankruptcy filing.BenzingaUS Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July - Acumen Pharmaceuticals (NASDAQU.S. stocks edged higher on Monday with the Dow, NASDAQ, and S&P 500 posting modest gains, while the NY Empire State Manufacturing Index fell to +1.1 in July, beating market estimates. In biotech trading, ProMIS Neurosciences and BridgeBio Pharma surged following positive clinical data presentations, whereas Novan and ViewRay plummeted after filing for Chapter 11 bankruptcy protection.GlobeNewswireNovan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNovan, Inc. has entered into a stalking horse asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of its assets, including its berdazimer gel product, while filing for Chapter 11 bankruptcy protection in the U.S. The $15 million cash transaction includes a secured debtor-in-possession financing commitment from Ligand and is subject to court approval and potential competing bids. Novan will continue operating as a debtor-in-possession to pursue FDA approval for its drug ahead of the January 2024 PDUFA goal date.BioSpaceNovan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNovan, Inc. entered into a stalking horse asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of its assets, including the berdazimer gel product, prior to filing for Chapter 11 bankruptcy protection. As part of the deal, Ligand committed to providing $15 million in debtor-in-possession financing and $3 million in a pre-petition bridge loan to support Novan's operations during the bankruptcy process. The transaction allows Novan to continue working toward FDA approval for its lead drug while managing its challenging financial circumstances.GlobeNewswireNovan to Report Full Year 2022 Financial Results on March 30, 2023Novan, Inc. will report its full year 2022 financial results on March 30, 2023, with a conference call at 8:30 a.m. ET. The call will be led by CEO Paula Brown Stafford, and the webcast will be archived for 90 days.BioSpaceNovan Announces $6.0 Million Registered Direct OfferingNovan, Inc. announced a registered direct offering of 5,042,017 shares and warrants at $1.19 per share, with gross proceeds expected to be approximately $6.0 million. The company will use the net proceeds to fund its berdazimer gel development, support sales and marketing, and for general working capital. The offering is expected to close on or about March 16, 2023.BioSpaceNovan Moves Forward with Unified Corporate BrandingNovan announced that its commercial subsidiary EPI Health will adopt the Novan brand, unifying under one name. The company has an NDA submission for berdazimer gel, 10.3% (SB206) for molluscum contagiosum, and aims to streamline pre-commercial activities. The unified brand supports the potential commercial launch of the gel.GlobeNewswireNovan to Present at the Virtual Investor 2023 Companies to Watch EventNovan, Inc. announced that CEO Paula Brown Stafford will present at the Virtual Investor 2023 Companies to Watch Event on January 19, 2023. The live webcast will be available on the company's website, with a replay accessible for 90 days.